title: CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer.
abstract: CYFRA 21-1 is a new tumor marker using two different monoclonal antibodies which recognize the divergent epitope on the N- or C-terminal region of domain 2 of cytokeratin 19 fragment, respectively. In this study, we investigated the relationship between levels of CYFRA 21-1 and survival duration, as well as the efficacy of chemotherapy associated with changes in CYFRA 21-1. Serum samples were obtained from 87 patients with nonoperable lung cancer (35 cases with squamous-cell carcinoma, 33 with adenocarcinoma, 3 with large-cell carcinoma, and 16 with small-cell carcinoma). The cutoff point was set at 3.5 ng/ml. In a CYFRA 21-1 assay, significantly more patients with squamous-cell carcinoma and adenocarcinoma were positive compared to patients with small-cell and large-cell carcinomas (p = 0.0017). Following chemotherapy, blood levels of CYFRA 21-1 decreased significantly in responders versus nonresponders (p = 0.0246). A significant correlation was noted between survival periods and pretreatment levels of CYFRA 21-1 (p = 0.0036). The present study suggests that CYFRA 21-1 might be useful as a possible indicator of survival and therapeutic effect for lung cancer.
authors.affiliation: First Department of Internal Medicine, Gunma University School of Medicine, National Nishi-Gunma Hospital, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Takei
authors.forename: K
authors.initials: K
authors.lastname: Minato
authors.forename: S
authors.initials: S
authors.lastname: Tsuchiya
authors.forename: A
authors.initials: A
authors.lastname: Takise
authors.forename: H
authors.initials: H
authors.lastname: Nakano
authors.forename: K
authors.initials: K
authors.lastname: Ezawa
authors.forename: N
authors.initials: N
authors.lastname: Fueki
authors.forename: H
authors.initials: H
authors.lastname: Hoshino
authors.forename: I
authors.initials: I
authors.lastname: Naruse
authors.forename: T
authors.initials: T
authors.lastname: Nomoto
authors.forename: T
authors.initials: T
authors.lastname: Makimoto
authors.forename: S
authors.initials: S
authors.lastname: Ishihara
authors.forename: R
authors.initials: R
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Mori
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002277:Carcinoma / Q000276:immunology* / Q000628:therapy; D005260:Female; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D008175:Lung Neoplasms / Q000276:immunology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D053539:Keratin-19; C102012:antigen CYFRA21.1; D007633:Keratins